NASDAQ:STOK Stoke Therapeutics (STOK) Stock Price, News & Analysis $13.25 +0.08 (+0.61%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$13.25 0.00 (0.00%) As of 08/7/2025 07:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Stoke Therapeutics Stock (NASDAQ:STOK) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Stoke Therapeutics alerts:Sign Up Key Stats Today's Range$12.86▼$13.2750-Day Range$9.61▼$14.2752-Week Range$5.35▼$16.15Volume418,198 shsAverage Volume784,097 shsMarket Capitalization$723.45 millionP/E Ratio16.77Dividend YieldN/APrice Target$25.80Consensus RatingBuy Company Overview Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts. Read More Stoke Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks79th Percentile Overall ScoreSTOK MarketRank™: Stoke Therapeutics scored higher than 79% of companies evaluated by MarketBeat, and ranked 207th out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingStoke Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.29, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageStoke Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Stoke Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Stoke Therapeutics are expected to decrease in the coming year, from ($2.01) to ($2.27) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Stoke Therapeutics is 16.77, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 27.77.Price to Earnings Ratio vs. SectorThe P/E ratio of Stoke Therapeutics is 16.77, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 29.85.Price to Book Value per Share RatioStoke Therapeutics has a P/B Ratio of 3.07. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted21.06% of the outstanding shares of Stoke Therapeutics have been sold short.Short Interest Ratio / Days to CoverStoke Therapeutics has a short interest ratio ("days to cover") of 16.6, which indicates bearish sentiment.Change versus previous monthShort interest in Stoke Therapeutics has recently decreased by 0.26%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldStoke Therapeutics does not currently pay a dividend.Dividend GrowthStoke Therapeutics does not have a long track record of dividend growth. Sustainability and ESG4.8 / 5Environmental Score-0.59 Percentage of Shares Shorted21.06% of the outstanding shares of Stoke Therapeutics have been sold short.Short Interest Ratio / Days to CoverStoke Therapeutics has a short interest ratio ("days to cover") of 16.6, which indicates bearish sentiment.Change versus previous monthShort interest in Stoke Therapeutics has recently decreased by 0.26%, indicating that investor sentiment is improving. News and Social Media1.8 / 5News Sentiment0.31 News SentimentStoke Therapeutics has a news sentiment score of 0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Stoke Therapeutics this week, compared to 5 articles on an average week.Search Interest11 people have searched for STOK on MarketBeat in the last 30 days. This is an increase of 1,000% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Stoke Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Stoke Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $140,095.00 in company stock.Percentage Held by InsidersOnly 9.50% of the stock of Stoke Therapeutics is held by insiders.Read more about Stoke Therapeutics' insider trading history. Receive STOK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Stoke Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address STOK Stock News HeadlinesStoke Therapeutics to Present at the Canaccord Genuity 45th Annual Growth ConferenceAugust 6 at 5:06 PM | businesswire.comStoke Therapeutics (STOK) Expected to Announce Quarterly Earnings on WednesdayAugust 5 at 2:31 AM | americanbankingnews.comGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. Backed by the government but powered by private corporations, this initiative paves the way for digital dollars—programmable, trackable, and outside your control. Once embedded into apps, banks, and retail systems, opting out may no longer be possible. But there’s still time to protect your financial freedom—if you act before the system goes fully live. | Priority Gold (Ad)The Oligonucleotide Therapeutics Society Announces the 21st Annual Meeting in Budapest, HungaryAugust 1, 2025 | msn.comStoke Therapeutics, Inc. (NASDAQ:STOK) Receives $25.80 Consensus Target Price from AnalystsJuly 30, 2025 | americanbankingnews.comStoke Therapeutics Inc. Stock Grades | STOK | Barron'sJuly 28, 2025 | barrons.comJefferies Initiates Coverage of Stoke Therapeutics (STOK) with Buy RecommendationJuly 19, 2025 | msn.comJefferies starts Stoke at Buy, sees $1 bln+ opportunity in rare epilepsy drugJuly 19, 2025 | finance.yahoo.comSee More Headlines STOK Stock Analysis - Frequently Asked Questions How have STOK shares performed this year? Stoke Therapeutics' stock was trading at $11.03 on January 1st, 2025. Since then, STOK shares have increased by 20.1% and is now trading at $13.25. How were Stoke Therapeutics' earnings last quarter? Stoke Therapeutics, Inc. (NASDAQ:STOK) released its earnings results on Monday, March, 24th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.56) by $0.38. The company earned $22.61 million during the quarter, compared to the consensus estimate of $4.20 million. Stoke Therapeutics had a trailing twelve-month return on equity of 19.08% and a net margin of 26.33%. When did Stoke Therapeutics IPO? Stoke Therapeutics (STOK) raised $100 million in an initial public offering on Wednesday, June 19th 2019. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen and Credit Suisse acted as the underwriters for the IPO and Canaccord Genuity was co-manager. Who are Stoke Therapeutics' major shareholders? Top institutional shareholders of Stoke Therapeutics include Skorpios Trust (5.96%), Assenagon Asset Management S.A. (0.99%), Aviva PLC (0.08%) and Allspring Global Investments Holdings LLC (0.06%). Insiders that own company stock include Skorpios Trust, Edward M Md Kaye, Jonathan Allan, Stephen J Tulipano and Barry Ticho. View institutional ownership trends. How do I buy shares of Stoke Therapeutics? Shares of STOK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Stoke Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Stoke Therapeutics investors own include Enovix (ENVX), Rambus (RMBS), COMPASS Pathways (CMPS), Globant (GLOB), Ginkgo Bioworks (DNA), Toast (TOST) and Saia (SAIA). Company Calendar Last Earnings3/24/2025Today8/07/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:STOK CIK1623526 Webwww.stoketherapeutics.com Phone(781) 430-8200FaxN/AEmployees100Year FoundedN/APrice Target and Rating Average Price Target for Stoke Therapeutics$25.80 High Price Target$35.00 Low Price Target$18.00 Potential Upside/Downside+94.7%Consensus RatingBuy Rating Score (0-4)3.29 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)$0.79 Trailing P/E Ratio16.77 Forward P/E RatioN/A P/E GrowthN/ANet Income-$88.98 million Net Margins26.33% Pretax Margin27.00% Return on Equity19.08% Return on Assets15.72% Debt Debt-to-Equity RatioN/A Current Ratio8.41 Quick Ratio8.41 Sales & Book Value Annual Sales$190.91 million Price / Sales3.79 Cash FlowN/A Price / Cash FlowN/A Book Value$4.32 per share Price / Book3.07Miscellaneous Outstanding Shares54,597,000Free Float49,410,000Market Cap$723.41 million OptionableOptionable Beta1.15 Social Links The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:STOK) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Stoke Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Stoke Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.